Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

TNF-α Impairs Regulatory T Cells in Patients with Rheumatoid Arthritis

Lara C. Pullen, PhD  |  June 3, 2013

New research elucidates the role of tumor necrosis factor (TNF)–α in immune regulation in patients with rheumatoid arthritis (RA). Hong Nie, MD, PhD, of the Shanghai Jiao Tong University School of Medicine in China, and colleagues examined the synovium of patients with RA in order to better understand the relationship between regulatory T (Treg) cells and pathogenic T cells. The results were published in Nature Medicine.1

Previous studies have noted that the number/percentage of Treg cells does not differ between the synovial fluid of healthy individuals and individuals with RA. Thus, patients with RA have synovial inflammation despite normal levels of Treg cells.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“This paradox triggered our interest and prompted us to investigate the underlying mechanism. We later discovered that synovial Treg cells had no regulatory function and that there was a posttranslational defect in FOXP3 (FOXP3 was not properly phosphorylated),” explained Jingwu Z. Zhang, also of the Shanghai Jiao Tong University School of Medicine, by e-mail.

The authors found that TNF-α induces FOXP3 dephosphorylation, thereby controlling the balance of Treg cells and pathogenic Th17 and Th1 cells. The improper phosphorylation of FOXP3 translates into severely impaired regulatory function.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Thus, aberrant TNF-α production in the synovium drives a pathological circuit by inducing macrophage-produced protein phosphatase 1 (PP1). PP1 then dephosphorylates the Ser418 phosphorylation site of the FOXP3 in Treg cells.

When the authors treated patients with RA with TNF-α–specific antibody, they were able to restore Treg cell function. They also found an associated decrease in PP1 expression and increased FOXP3 phosphorylation in Treg cells.

“This post translational defect of FOXP3/Treg cells can be corrected by giving TNF-α blockers. The conclusion of the study provides a powerful mechanistic explanation as to why TNF-α works in RA as a disease-modifying treatment,” wrote Dr. Zhang.

Many inflammatory diseases have impaired Treg cells. It may be that FOXP3 and other transcription factors are influenced and/or impaired by the local proinflammatory cytokine milieu. The transcription factors may be modified at a posttranslational or epigenetic level by the cytokines explained Dr. Zhang.

These results add to previous studies that have demonstrated that protein kinase C-θ (PKC-θ) mediates the inhibitory effects of TNF-α on Treg cells.


Dr. Pullen is a medical writer based in the Chicago area.

Reference

  1. Nie H, Zheng Y, Li R, et al. Phosphorylation of FOXP3 controls regulatory T cell function and is inhibited by TNF-α in rheumatoid arthritis. Nat Med. 2013;19:322-328.

     

Page: 1 2 | Single Page
Share: 

Filed under:Uncategorized Tagged with:Rheumatoid arthritisT-cellsTNF

Related Articles

    Treg Cells May Orchestrate Muscle Repair after Injury

    May 30, 2014

    New research shows the accumulation of regulatory T cells in damaged muscle corresponds with a switch in the myeloid cell infiltrate from a proinflammatory to a proregenerative phenotype.

    2014 ACR/ARHP Annual Meeting: Regulatory T Cells

    April 1, 2015

    Rheumatology experts explore ways Treg cells contribute to autoimmune diseases, RA

    Protein Phosphatase 2A and Regulatory T Cell Function Researched

    June 13, 2016

    The serine-threonine protein phosphatase 2A (PP2A) enzyme is critical for regulatory T cells to function—without it, they don’t have the ability to suppress effector T cells and can’t protect against autoimmunity, according to new research published in Nature Immunology. Researchers found that conditional knockout mice—in which PP2A expression is knocked out only in regulatory T cells—developed…

    In Memoriam: Shunle Chen, MD

    March 15, 2021

    It is with great sadness that we report the passing of a giant of international rheumatology, Professor Shunle Chen. He was a friend, colleague, collaborator, visionary leader and inspiration to many rheumatologists in China and the world. Moreover, despite his inter­national stature, he was a warm friend and nurturing mentor to all those who had…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences